Parallel Advisors, LLC Ascendis Pharma A/S Transaction History
Parallel Advisors, LLC
- $4.18 Billion
- Q3 2024
A detailed history of Parallel Advisors, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Parallel Advisors, LLC holds 156 shares of ASND stock, worth $21,476. This represents 0.0% of its overall portfolio holdings.
Number of Shares
156
Previous 156
-0.0%
Holding current value
$21,476
Previous $21,000
9.52%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.34 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$707 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$687 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$607 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$576 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.68B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...